

Supplementary Table 1 | Changes of serum tumor and inflammatory makers between TACE and HAIC group.

Lab findings	TACE (n=91)			HAIC (n=190)		
	Before	After	P-value	Before	After	P-value
AFP	32834.8 ±	30697.8 ±	0.299	31032.1 ±	21865.0 ±	<0.001
	46618.8	43022.6		46919.3	43031.8*	
PIVKA II	21559.2 ±	22170.5 ±	0.181	23157.0 ±	16996.1 ±	<0.001
	28021.2	28808.8		28196.5	28672.6*	
CRP	17.3 ± 30.5	34.6 ± 42.5*	<0.001	20.7 ± 30.5	21.7 ± 42.6	0.233
NLR	2.8 ± 1.8	3.9 ± 14.4*	0.006	3.4 ± 1.8	5.7 ± 14.4	0.202
PLR	145.9 ± 90.2	152.8 ± 114.0	0.394	159.9 ± 97.1	136.5 ± 114.0*	<0.001
SII	601.5 ± 608.5	706.3 ± 2042.1	0.354	757.6 ± 609.9	843.2 ± 2041.9*	<0.001
PNI	48.7 ± 5.6	44.9 ± 7.1*	<0.001	48.6 ± 5.6	45.2 ± 7.0*	<0.001

Changes of serum tumor and inflammatory makers between TACE and HAIC group (PSM)

Lab findings	TACE (n=77)			HAIC (n=77)		
	Before	After	P-value	Before	After	P-value
AFP	36020.6 ±	34718.3 ±	0.246	31817.8 ±	25746.6 ±	0.041
	50408.8	49458.9		48131.7	44440.1*	
PIVKA II	22779.0 ±	23526.8 ±	0.181	24151.8 ±	16536.8 ±	<0.001
	27265.6	31314.7		29107.3	27118.5*	
CRP	19.0 ± 26.1	36.7 ± 47.6*	<0.001	25.3 ± 43.6	28.4 ± 57.5	0.128
NLR	2.9 ± 1.5	3.9 ± 3.8*	0.035	3.4 ± 2.0	5.1 ± 9.5	0.527
PLR	154.0 ± 98.1	152.8 ± 137.0	0.394	162.9 ± 109.6	135.3 ± 94.0*	0.020
SII	644.1 ± 518.1	747.5 ± 993.9	0.545	780.2 ± 701.7	830.7 ± 1808.6*	0.010
PNI	49.3 ± 5.1	45.6 ± 6.7*	<0.001	48.7 ± 5.4	44.5 ± 7.0*	<0.001

AFP, Alpha-fetoprotein; PIVKA II , Protein Induced by Vitamin K Absence or Antagonist-II; CRP, C-reactive protein; NLR, Neutrophil-to-lymphocyte ratio, PLR, Platelet-to-lymphocyte ratio; SII, Systemic immune-inflammation index; PNI, prognostic nutritional index; PSM, propensity score matching; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy.

Data were continuous variables, expressed in (median ± standard deviation). Data in two groups were compared by using the Wilcoxon signed-rank test or matched samples t-test.